#Breaking: The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease. Learn more: bit.ly/4apMw9p
- The UK Medicines and Healthcare products Regulatory Agency approves the CRISPR/Cas9 gene-edited treatment for #SickleCellDisease & #BetaThalassemia in Great Britain. This is a historic milestone arising out of our collaboration with Vertex. Learn more: crisprtx.com
- The U.S. FDA approves the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for transfusion-dependent beta thalassemia. Learn more: bit.ly/47yIgS1
- #Breaking: The European Commission approves CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia for the European Union. Learn more: bit.ly/3IifYkR
- CRISPR Therapeutics and Vertex are pleased to share that we completed our regulatory submissions for exa-cel for sickle cell disease and beta thalassemia in the EU and the UK in December 2022.
- We are pleased to announce that we’ve completed the submission of our Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia. Learn more: bit.ly/3K2P7cR
- Today, we provided an update on our immuno-oncology pipeline of CRISPR/Cas9 gene-edited allogeneic chimeric antigen receptor (CAR) T cell product candidates and we announced expansion into autoimmune disease. Learn more here: bit.ly/4a8zpsM
- Today, @CRISPRTX and @ViaCyte announced the approval of our Clinical Trial Application (CTA) for type 1 diabetes (T1D). Read more here: bit.ly/3DnxsIk
- Today, @CRISPRTX and @ViaCyte announced that the first patient has been dosed in the Phase 1 clinical trial of VCTX210 for the treatment of type 1 diabetes (T1D). Read more here: bit.ly/3ofGfpZ
- The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for the conditional approval of the CRISPR/Cas9 gene-edited treatment, co-developed with Vertex Pharmaceuticals, for #SickleCellDisease and #BetaThalassemia.
- CRISPR Therapeutics and Vertex are pleased to share that the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) have validated the regulatory submissions of our potential treatment for sickle cell disease and beta thalassemia.
- We are pleased to announce that FDA has accepted our biologics license applications for our potential treatment for sickle cell disease and transfusion-dependent beta thalassemia. Our application for sickle cell disease has been granted priority review: bit.ly/45Ss5iY
- We’re proud to share that we’ve been named on the @TIME Best Inventions of 2024 list! This list recognizes a wide variety of new products, software or services that are making a difference in the world. #TIMEBestInventions
- We’re at #ASH21 alongside experts in the #hematology field to learn from our peers and spread awareness as we continue our work to potentially treat #sicklecelldisease, #betathalassemia and #bloodcancers. If you’re attending the @ASH_hematology meeting, come by our booth #3323.
